ABOUT ENZYCHEM LIFESCIENCES
Enzychem Lifesciences (KOSDAQ:183490) is developing novel small molecule therapeutics to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, we developed our leading candidate EC-18(Mosedipimod), an oral small molecule derived from Sika deer antler, which has shown to be active across a number of different indications.
LIPID MEDICINE PLATFORM TECHNOLOGY
EC-18 targets anti-inflammatory
pathway
Broad therapeutic platform
Developing first-in-class small molecules to target
fundamental inflammation pathways
EC-18 PIPELINE
DEVELOPMENT STAGE
CRIOM: Chemoradiation-induced Oral Mucositis
CIN: Chemotherapy-induced Neutropenia
ARS: Acute Radiation Syndrome
COVID-19: Coronavirus Disease-19
ICI: Immune Checkpoint Inhibitors (PD-1, PD-L1)
NASH: Non-alcoholic Steatohepatitis
Press Releases
Enzychem Lifesciences Announces Acceptance of EC-18 Abstract for Oral Proffered Paper at the MASCC/ISOO 2022 Annual Meeting
ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today that the abstract has been accep
Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting
ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced that it will present new Phase 2 US cl
Enzychem Lifesciences Announces Completion of Clinical Study Report (CSR) for Phase 2 Study of EC-18 in Chemoradiation-Induced Oral Mucositis
ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biotechnology company, announced today that the company has completed t